Maravai LifeSciences Holdings Management
Management criteria checks 4/4
Maravai LifeSciences Holdings' CEO is Trey Martin, appointed in Jul 2023, has a tenure of 1.42 years. total yearly compensation is $2.30M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $1.48M. The average tenure of the management team and the board of directors is 2.2 years and 4.1 years respectively.
Key information
Trey Martin
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 32.6% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.2yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Maravai LifeSciences: Still Struggling To Find Its Footing
Nov 25Slammed 37% Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Screens Well Here But There Might Be A Catch
Nov 11
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Oct 15Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Jul 18Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Jul 15Maravai: Embedded Expectations Remain Too High Considering Economic Calculus
Jul 12RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$225m |
| Jun 30 2024 | n/a | n/a | -US$132m |
| Mar 31 2024 | n/a | n/a | -US$131m |
| Dec 31 2023 | US$2m | US$750k | -US$119m |
| Sep 30 2023 | n/a | n/a | US$25m |
| Jun 30 2023 | n/a | n/a | US$75m |
| Mar 31 2023 | n/a | n/a | US$153m |
| Dec 31 2022 | US$15m | US$660k | US$220m |
Compensation vs Market: Trey's total compensation ($USD2.30M) is below average for companies of similar size in the US market ($USD5.54M).
Compensation vs Earnings: Trey's compensation has been consistent with company performance over the past year.
CEO
Trey Martin (49 yo)
1.4yrs
Tenure
US$2,301,864
Compensation
Mr. William E. Martin, III, also known as Trey, is Director of Maravai LifeSciences Holdings, Inc. from July 31, 2024. He was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$2.30m | 0.11% $ 1.5m | |
| Executive VP & CFO | 7.6yrs | US$2.79m | 0.022% $ 301.0k | |
| Executive VP & Chief Administrative Officer | 2.5yrs | US$2.83m | 0.039% $ 535.4k | |
| Executive VP & GM of Cygnus Technologies | 7.2yrs | US$2.26m | 0.020% $ 266.6k | |
| President of Nucleic Acid Production | 1.8yrs | US$2.99m | 0.024% $ 323.2k | |
| Chairman of the Board | no data | no data | no data | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Executive VP | 4.1yrs | US$701.40k | 0.018% $ 248.0k | |
| Executive VP & Chief Commercial Officer | 1.8yrs | no data | 0.021% $ 283.8k | |
| Chief Innovation Officer | 1.8yrs | no data | no data |
2.2yrs
Average Tenure
55yo
Average Age
Experienced Management: MRVI's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$2.30m | 0.11% $ 1.5m | |
| Chairman of the Board | no data | no data | no data | |
| Independent Director | 1.4yrs | US$435.03k | 0.020% $ 268.9k | |
| Non-Independent Director | 4.1yrs | US$370.48k | 0.0030% $ 40.8k | |
| Non-Independent Director | 4.1yrs | US$367.98k | 0.0030% $ 40.8k | |
| Independent Director | 4.1yrs | US$360.48k | 0.039% $ 527.0k | |
| Independent Director | 4.1yrs | US$395.48k | 0.025% $ 345.4k | |
| Non-Independent Director | 4.1yrs | US$360.48k | 0.0030% $ 40.8k | |
| Non-Independent Director | 4.1yrs | US$360.48k | 0.0030% $ 40.8k | |
| Independent Director | 4.1yrs | US$367.98k | 0.015% $ 199.1k | |
| Independent Director | 4.1yrs | US$387.98k | 0.047% $ 632.2k |
4.1yrs
Average Tenure
59yo
Average Age
Experienced Board: MRVI's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:06 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Maravai LifeSciences Holdings, Inc. is covered by 17 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |